A Clinical Study to Evaluate the Safety & Tolerability of JS107 in

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05028933` - IMC001 for Clinical Research on Advanced Digestive System Malignancies	Phase 1
Not yet recruiting	`NCT03662035` - Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer	Phase 2
Recruiting	`NCT05085548` - ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies	Phase 1
Recruiting	`NCT06111274` - A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer	Phase 2
Active, not recruiting	`NCT04137536` - A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer	Phase 1
Completed	`NCT04617067` - Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer	Phase 2
Active, not recruiting	`NCT04469556` - Pancreatic Adenocarcinoma Signature Stratification for Treatment	Phase 2
Active, not recruiting	`NCT04104672` - A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies	Phase 1
Not yet recruiting	`NCT05100329` - A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer	Phase 2
Completed	`NCT02101580` - Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer	Phase 1
Recruiting	`NCT02135822` - Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer	Phase 2
Recruiting	`NCT04803851` - Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer	Phase 1/Phase 2
Completed	`NCT03415802` - Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer	Phase 2
Recruiting	`NCT05162118` - Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT06329947` - A Phase II Study of Surufatinib Combined With PD-L1 and mFOLFOX6 as Second-line Treatment for Advanced PRAD	Phase 2
Recruiting	`NCT04643405` - APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma	Phase 1/Phase 2
Recruiting	`NCT03889795` - Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors	Phase 1
Completed	`NCT01303172` - A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer	Phase 2
Recruiting	`NCT04931381` - Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer	Phase 3
Recruiting	`NCT04482257` - Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.	Phase 1

NCT number	NCT05657418
Study type	Interventional
Source	Shanghai Junshi Bioscience Co., Ltd.
Contact	Xiaohong Ding, PM
Phone	86 021-61058800
Email	xiaohong_ding@junshipharma.com
Status	Not yet recruiting
Phase	Phase 1
Start date	December 30, 2022
Completion date	December 30, 2024

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms